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A targeted Quantitative proteomic 
Method Revealed a Substantial 
Reprogramming of Kinome during 
Melanoma Metastasis
Weili Miao1, Lin Li1, Xiaochuan Liu1, tianyu f. Qi2, Lei Guo2, Ming Huang2 &  
Yinsheng Wang  1,2*
Kinases are involved in numerous critical cell signaling processes, and dysregulation in kinase signaling 
is implicated in many types of human cancers. in this study, we applied a parallel-reaction monitoring 
(pRM)-based targeted proteomic method to assess kinome reprogramming during melanoma 
metastasis in three pairs of matched primary/metastatic human melanoma cell lines. Around 300 
kinases were detected in each pair of cell lines, and the results showed that Janus kinase 3 (JAK3) was 
with reduced expression in the metastatic lines of all three pairs of melanoma cells. interrogation of 
The Cancer Genome Atlas (TCGA) data showed that reduced expression of JAK3 is correlated with 
poorer prognosis in melanoma patients. Additionally, metastatic human melanoma cells/tissues 
exhibited diminished levels of JAK3 mRNA relative to primary melanoma cells/tissues. Moreover, JAK3 
suppresses the migration and invasion of cultured melanoma cells by modulating the activities of matrix 
metalloproteinases 2 and 9 (MMP-2 and MMP-9). In summary, our targeted kinome profiling method 
provided by far the most comprehensive dataset for kinome reprogramming associated with melanoma 
progression, which builds a solid foundation for examining the functions of other kinases in melanoma 
metastasis. Moreover, our results reveal a role of JAK3 as a potential suppressor for melanoma 
metastasis.
Kinases constitute crucial elements in cell signaling, and in regulation of cell proliferation and metabolism1,2. 
Aberrant expression and/or activation of kinases have been observed in cancer and many other human dis-
eases3. Melanoma is a common type of cancer, and its metastasis leads to the majority of mortality in melanoma 
patients4. Aberrant kinase activation is associated with melanoma. For instance, BRAF V600E and V600K muta-
tions, which lead to constitutive activation of the kinase, are among the most frequent genetic alterations found 
in melanoma patients5. Dabrafenib and vemurafenib, which bind to BRAF and inhibit its kinase activity, are Food 
and Drug Administration (FDA)-approved drugs for the treatment of metastatic melanoma6. However, patients 
treated with these BRAF inhibitors relapse at 6–8 months after therapy7. Immunotherapy relying on checkpoint 
blockade can allow for relapse-free remission of melanoma; the response rate, nevertheless, is low8. Hence, it’s 
important to develop new and effective therapeutic approaches for melanoma treatment. We reason that the iden-
tification of those kinases that promote or suppress melanoma metastasis will improve our understanding about 
the etiology of melanoma progression and may reveal novel targets for its therapeutic intervention.
Several methods have been developed for the quantification of kinase proteins at the entire proteome level. For 
example, isotope-coded ATP-affinity probes were shown to be effective in the covalent labeling and enrichment of 
kinase proteins or their component peptides for subsequent LC-MS/MS analysis9–11. Both the protein expression 
level of a kinase and its ATP-binding affinity can affect the extent of kinase labeling by the ATP affinity probe, 
where the ATP binding affinity of a kinase is sometimes modulated by its activity12. Additionally, affinity resin 
immobilized with various kinase inhibitors was utilized for kinase protein enrichment, where the enrichment 
efficiency may also be impacted by kinase activity13–15. Recently, we developed a parallel-reaction monitoring 
(PRM)-based targeted proteomic method for assessing specifically the kinase protein expression at the entire pro-
teome scale12. In this regard, we established a Skyline LC-PRM library for kinome analysis based on the shotgun 
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proteomic data collected by analyzing tryptic digestion mixtures from multiple human cell lines12. The library 
encompasses 1050 tryptic peptides representing 478 kinase proteins, and 395 of them are protein kinases12,16–18.
In this work, we applied the recently established PRM-based targeted proteomic method12, in combination 
with stable isotope labeling by amino acids in cell culture (SILAC), to examine the differential protein expression 
of kinases in 3 pairs of matched primary/metastatic melanoma cells. We were able to quantify the relative expres-
sion levels of approximately 300 unique kinase proteins in each pair of cell lines. Among them, JAK3, MAP4K4 
and CCNH were consistently down-regulated in the metastatic lines of all three pairs of melanoma cells. Analysis 
of publicly available data also showed that elevated JAK3 expression is correlated with improved survival of mel-
anoma patients. We further demonstrated that JAK3 suppresses the migratory and invasive abilities of melanoma 
cells in vitro, which involves diminished enzymatic activities of secreted matrix metalloproteinases.
Results
Quantitative assessment of the differential expression of kinase proteins in primary and met-
astatic human melanoma cells. Our primary objective was to explore the potential roles of kinases in 
melanoma metastasis. Toward this end, we applied a PRM-based targeted proteomic method12, in combination 
with SILAC19, to examine the differences in kinase protein expression in 3 pairs of primary/metastatic mela-
noma cells (i.e. IGR-39/IGR-37, WM-115/WM-266-4, and WM-793/1205Lu) (Fig. 1a). In this vein, WM-115 
and WM-266-4 cells were derived from the primary and skin metastatic sites of the same melanoma patient, 
respectively20, and IGR-39 and IGR-37 cells were initiated respectively from the primary and groin metastatic 
sites of another melanoma patient21. On the other hand, 1205Lu cells were originated from a lung metastasis in 
an immune-deficient mouse through tail-vein injection of WM-793 human melanoma cells, which were initiated 
from a superficial spreading melanoma22.
The proteomic results led to the quantification of approximately 300 unique kinases in each pair of melanoma 
cells, including 237–252 protein kinases, along with many lipid, carbohydrate and nucleotide kinases (Figs. S1–S3, 
Tables 1 and S1). All 4–6 PRM transitions used for the quantification of every kinase peptide displayed the same 
retention time and exhibited a dot product (dotp) value of >0.7 (Fig. S4)23. In addition, over 90% of the quantified 
kinase peptides showed consistent trends in forward and reverse SILAC labeling experiments (Fig. 1b,c, Table S1, 
and representative results for AK1 are shown in Fig. S5b). Along this line, owing to the complex matrices for the 
samples employed for the LC-PRM analysis (i.e. the tryptic digestion mixtures of whole-cell protein lysates), a 
somewhat modest R2 value (0.50) was found for the correlation between the ratios obtained from forward and 
reverse SILAC labeling experiments (Fig. 1c). Based on the range of signal intensities detected for the kinase pep-
tides, we estimated that the PRM method exhibits a dynamic range of 4 orders of magnitude (Fig. 1d).
A comparison of the kinome quantification results revealed that the IGR-39/IGR-37and WM-115/WM-266-4 
pairs of melanoma cells displayed many similar attributes in metastasis-associated alterations in expression 
levels of kinases. However, the results for these two pairs differed substantially from those obtained for the 
WM-793/1205Lu pair (Fig. 2 and Table S1). This might be attributed to the facts that melanoma is a highly het-
erogeneous disease24 and that the metastatic lines from the first two pairs were derived from metastasis in mela-
noma patients, whereas that of the last pair was from experimental metastasis in a mouse22.
We also validated the protein expression levels for six quantified kinases (AK1, JAK3, PAK1, PAK2, SCYL3 
and STK26) by Western analysis and the results are all in agreement with what we obtained from PRM measure-
ment (Fig. 3), supporting that the LC-PRM method, in conjunction with SILAC labeling, afforded robust quanti-
fication of kinase proteins. In this vein, it’s worth noting that the PRM-based LC-MS/MS quantification method 
relies on unique peptide sequences of kinases; hence, the method can distinguish different kinase isoforms. For 
instance, the method allowed for the independent quantifications of PAK1 and PAK2 (Fig. 3c). The PAK antibody 
that we used for Western blot analysis can recognize all three isoforms of PAK (i.e. PAK1, PAK2, and PAK3). 
While the peptides derived from PAK3 were below the detection limit of the PRM method, the peak intensity 
observed for the PAK2 peptide is approximately 10-fold higher than that for the PAK1 peptide, which is consist-
ent with the Western blot results. These observations, in conjunction with the similar molecular weights of PAK1 
and PAK3, allow us to assign the higher-molecular weight band observed in Western blot exclusively to PAK1.
We further performed KEGG pathway analysis25 on the basis of those kinases that are up-regulated in the 
metastatic WM-266-4, IGR-37 and 1205Lu cells over the corresponding primary melanoma cells, and we found 
that many pathways, including those of MAPK signaling, cancer, focal adhesion and purine metabolism, were 
up-regulated (Fig. S6). Additionally, pathways in melanoma is up-regulated based on those kinases that are com-
monly up-regulated in the metastatic WM-266-4 and IGR-37 cells over the corresponding primary melanoma 
cells (Fig. S6).
Potential roles of JAK3 in melanoma progression. To identify potential drivers and suppressors for 
melanoma metastasis, we compared the 130 perturbed kinases obtained from the PRM results of WM-115/
WM-266-4 pair of cells with the TCGA data collected for more than 400 melanoma patients26. We found that 
the mRNA expression levels of 19 differentially expressed kinases are correlated with the overall survival of mel-
anoma patients (Table S2, Logrank p-value < 0.05). Among these kinases, 6 (RPS6KB2, DSTYK, TBRG4, CDK4, 
POLR2E, FASTKD5) and 4 (STK26, PAK1, EPHB2 and JAK3) were consistently up- or down-regulated, respec-
tively, in the metastatic lines of at least two pairs of melanoma cells (Figs. 4b and S7). For instance, JAK3 displayed 
consistently lower levels of expression in all three metastatic lines of the paired melanoma cells (Fig. 3c,d). The 
same trend held for the mRNA expression levels (Fig. 4a).
JAK3, a tyrosine kinase involved in signal transduction by receptors27, was previously shown to assume impor-
tant roles in multiple types of cancer. For instance, JAK3 was demonstrated to promote breast cancer metastasis28. 
In addition, JAK3 exhibits high level of expression in leukemia (Fig. S8) and it was found to be frequently mutated 
in T-cell acute lymphoblastic leukemia29. Furthermore, JAK3 was shown to function together with STAT3 to 
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Figure 1. LC-PRM analysis, in conjunction with metabolic labeling using SILAC, for interrogating the 
differential expression of kinase proteins in paired primary/metastatic melanoma cells. (a) A schematic diagram 
showing the forward SILAC-based targeted proteomics workflow for human kinome analysis in paired primary/
metastatic human melanoma cells. (b) Venn diagrams showing the overlap between the numbers of kinases 
quantified from forward and reverse SILAC labeling experiments for the three pairs of primary/metastatic 
melanoma cells. (c) Correlation between the log2(Ratio) in kinase protein expression in WM-266-4 over WM-
115 cells obtained from forward and reverse SILAC labeling experiments. (d) Distribution of signal intensities 
for the quantified kinase peptides. The detailed quantification data, including the list of peptides employed for 
LC-PRM analyses, are shown in Table S1.
WM-115/WM-266-4 IGR-39/IGR-37 WM-793/1205Lu
Protein kinases 252 237 242
Lipid kinases 10 11 10
Nucleotide kinases 27 27 28
Carbohydrate kinases 12 13 12
Other kinases 5 6 6
Table 1. The numbers of protein, lipid, nucleotide, and carbohydrate kinases quantified in the three pairs of 
primary/metastatic melanoma cells.
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control cell migration, invasion and apoptosis30. The roles of JAK3 in melanoma progression, however, remain 
unclear. To address this, we first investigated whether JAK3 gene is expressed at different levels in metastatic and 
primary melanoma tissues by analyzing the data retrieved from the Gene Expression Omnibus (GEO) and CCLE 
datasets. In particular, an analysis of the GSE8401 dataset, which included 83 melanoma patients (31 primary and 
52 metastatic)31, revealed a significant down-regulation of JAK3 gene in the metastatic relative to primary mel-
anoma tissues (Fig. 4c). Analysis of the CCLE dataset also unveiled the diminished mRNA level of JAK3 gene in 
metastatic melanoma cell lines over primary melanoma lines (Figs. 4d and S8). Thus, our quantitative proteomic 
results, combined with TCGA data and other datasets, suggest that JAK3 may suppress melanoma metastasis.
JAK3 suppresses the invasion of cultured melanoma cells by regulating the activities of 
secreted metalloproteinases (MMps). We next studied the potential function of JAK3 in melanoma 
metastasis by asking how the capacities in migration and invasion of cultured melanoma cells are influenced 
by the expression levels of kinase proteins32. Our results from transwell migration and invasion assay showed 
that the WM-115 primary melanoma cells exhibited a modest, yet statistically significant increase in migratory 
capacity, and a marked elevation in invasive ability upon siRNA-mediated knock-down of JAK3 (Figs. 5a,c,d and 
S9). Reciprocal experiment showed that the overexpression of JAK3 in WM-266-4 metastatic melanoma cells 
suppressed their motility and invasion (Figs. 5b–d and S9).
Given that MMP-2 and MMP-9 play important roles in degrading extracellular matrix proteins and promot-
ing cancer metastasis33, we next investigated whether the enzymatic activities of MMP-2 &-9 could be modulated 
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Figure 2. A heatmap showing the differential expression of kinase proteins in 3 pairs of matched primary/
metastatic melanoma cell lines. The data represent the mean values of the results obtained from four replicates 
(two forward and two reverse SILAC labeling experiments) for the WM-115/WM-266-4 pair and two replicates 
each (one forward and one reverse SILAC labeling experiments) for the IGR-39/IGR-37 and WM-793/1205Lu 
pairs (see Table S1 for ratios obtained from individual biological replicates). Only those kinases that were 
commonly quantified in all three pairs of melanoma cells were plotted. Red and green boxes represent the up- 
and down-regulated kinases in metastatic over primary melanoma cells, respectively. Arrows indicate those 
kinases whose relative levels of expression in the 3 matched pairs of melanoma cells were validated by Western 
blot analyses (see Fig. 3).
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by JAK3 expression levels. We found, from gelatin zymography assay34, that the activities of secreted MMP-2 
MMP-9 were heightened in WM-115 primary melanoma cells upon siRNA-mediated knock-down of JAK3 
(Figs. 5e,g,h and S9). Reciprocally, ectopic overexpression of JAK3 in WM-266-4 metastatic melanoma cells led 
to diminished enzymatic activities of secreted MMP-2 &9 (Figs. 5f–h and S9). Together, the above results suggest 
that JAK3 impedes the invasion of melanoma cells in vitro, at least in part, by regulating the activities of secreted 
MMP-2 and MMP-9.
The epithelial-to-mesenchymal transition (EMT) is often accompanied with invasion of cancer cells, particu-
larly those of epithelial origin35, and JAK3 was shown to inhibit EMT by strengthening the adherens junctions36. 
Hence, we also examined the levels of expression of N-cadherin, an EMT marker, and our result showed that 
the N-cadherin protein was expressed at a higher level in WM-115 primary melanoma cells than WM-266-4 
metastatic melanoma cells (Fig. S10). Furthermore, siRNA-mediated knockdown of JAK3 resulted in diminished 
expression of N-cadherin (Fig. S10). Thus, EMT does not appear to contribute to elevated invasive capacity of 
the WM-266-4 melanoma cells, and the JAK3-mediated suppression of invasive capacity of melanoma cells is not 
attributed to EMT inhibition. This is in keeping with the previous finding that melanoma cells are not of epithelial 
origin37.
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Figure 3. Validation of quantification results for kinases obtained from the PRM-based targeted proteomic 
method. (a) Representative PRM traces for peptides from targeted kinases. Listed are the PRM traces of 
IGQPTLLLYVDAGPETMTQR from AK1 (y5, y6, y7, y8, y9, y10), SCSPSAEFLR from JAK3 (y3, y5, y6, y7, y8), 
NTSTMIGAGSK from PAK1 (y5, y6, y7, y8, y9), MTDEEIMEK from PAK2 (y3, y4, y5, y6, y7, y8), VILPQVLLGLR 
from SCYL3 (y4, y5, y6, y7, y8, y9) and SIAVAEAACPGITDK from STK26 (y3, y6, y7, y8, y9, y11). The y ions listed in 
the parentheses were the fragment ions observed in the MS/MS of the corresponding peptides that were chosen 
for peptide quantification. (b) Western blot for the validation of the expression levels of representative kinases in 
paired primary/metastatic melanoma cells. (c) Quantitative comparisons of ratios of kinase protein expression 
obtained from PRM (c) and Western blot (d) analyses. The data represent the mean ± S. D. of the quantification 
results (n = 3). The uncropped images for Western blot are provided in supporting information file.
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Discussion
Kinase- and phosphatase-mediated reversible phosphorylation of proteins and small molecules represents one 
of the most crucial and best characterized cell signaling pathways1,2. Thus, high-throughput kinome profiling 
constitutes a powerful approach for the systematic interrogation of kinase-modulated molecular events forged by 
extracellular cues and intracellular signaling. In this work, we applied a PRM-based targeted proteomic method 
to assess kinome reprogramming during melanoma metastasis, which led to the identification of novel kinases 
functioning as potential promoters or suppressors for melanoma metastasis. To our best knowledge, this is so far 
the most comprehensive kinome profiling dataset for melanoma metastasis.
We found that approximately half of the ~300 quantified kinases exhibited differential expression between 
primary and metastatic melanoma cells (Table S1). In combination with TCGA data, we discovered that JAK3 
plays important roles in melanoma progression. Furthermore, the mRNA expression of JAK3 was reduced in the 
metastatic over primary tumor tissues of melanoma patients, and in metastatic over primary melanoma cell lines 
(Fig. 4). Therefore, we further investigated JAK3’s roles in melanoma metastasis in vitro. Our results showed that 
reduced JAK3 expression is correlated with increased migration and invasion of cultured melanoma cells (Fig. 5). 
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Figure 4. Potential roles of JAK3 in melanoma progression. (a) The mRNA expression levels of JAK3 in 
WM-115, WM-266-4, IGR-39, and IGR-37 cell lines from CCLE database. (b) Kaplan-Meier plot showing the 
relationship between the mRNA expression levels of JAK3 gene and the overall survival of melanoma patients. 
The data were retrieved from TCGA database and analyzed using OncoLnc (http://www.oncolnc.org/). (c,d) 
The mRNA expression levels of JAK3 are down-regulated in metastatic melanoma tissues and cells relative to 
primary melanoma tissues and cells. Primary and metastatic melanoma patients in the GSE8401 dataset (c) and 
cells in the CCLE database (d) were employed for analysis. The displayed boxes contain the interquartile levels 
or z-scores of mRNA of JAK3 gene obtained from patients and cells. Shown by the whiskers extending outside of 
the box are the maximum and minimum mRNA level or z-scores of JAK3 expression from patients and cells.
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In addition, the activities of secreted MMPs are negatively correlated with the expression levels of JAK3 gene in 
primary and metastatic melanoma cells (Fig. 5), illustrating that JAK3 modulates melanoma cell invasion by 
regulating the activity of secreted MMPs. Along this line, protein interactome analysis demonstrated that JAK3 
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Figure 5. JAK3 modulates the migratory and invasive capacities of cultured melanoma cells through regulating 
the enzymatic activities of MMP-2 and MMP-9. (a) The migratory and invasive abilities of WM-115 primary 
melanoma cells upon siRNA-mediated knock-down of JAK3 gene. (b) The migratory and invasive abilities of 
WM-266-4 metastatic melanoma cells upon ectopic overexpression of JAK3 gene. (c,d) Quantification results 
for the migratory (c) and invasive (d) capacities of WM-115 cells upon knock-down of JAK3 gene and of WM-
266-4 cells upon overexpression of JAK3 gene. (e,f) Gelatin zymography assays showing the changes in activities 
of secreted MMP-2 and MMP-9 after siRNA-mediated knock-down of JAK3 gene in WM-115 cells (e) and upon 
ectopic overexpression of JAK3 gene in WM-266-4 cells (f). Shown on the left are the locations of molecular 
weight size markers (in kDa). (g,h) Quantification results for the activities of secreted MMP-2 (g) and MMP-9 
(h) in WM-115 upon knock-down of JAK3 and in WM-266-4 cells upon ectopic overexpression of JAK3. The 
data represent the mean ± S. D. of the quantification results (n = 3). The p values were calculated based on 
unpaired, two-tailed Student’s t-test: #, p ≥ 0.05; *0.01 ≤ p < 0.05; **0.001 ≤ p < 0.01; ***p < 0.001.
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interacts with BRMS1, which was shown to suppress melanoma metastasis38, and JAK3 co-expresses with another 
melanoma suppressor, EDAR (Fig. S11)39. Therefore, JAK3 may function together with BRMS1 and EDAR to 
suppress the migration and invasion of melanoma cells.
In summary, our targeted kinome profiling method provides a systematic assessment about kinome repro-
gramming during melanoma metastasis and our results provides important lines of evidence to support JAK3 as 
a potential suppressor for melanoma metastasis.
experimental procedures
cell culture. IGR-39/IGR-37 (generous gifts from Prof. Peter H. Duesberg, with BRAFV600E and P53C229fs)40, 
WM-793/1205Lu (The Wistar Institute, with BRAFV600E, P53WT and CDK4K22Q) cells were cultured in Dulbecco’s 
modified eagle medium (DMEM). WM-115/WM-266-4 cells (ATCC, with BRAFV600D and P53WT) were cultured 
in Eagle’s minimum essential medium (EMEM). All culture media were supplemented with 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA) and penicillin (100 IU/mL). The cells were kept in a humidified atmosphere 
with 5% CO2 at 37 °C. Approximately 2 × 107 cells were harvested, followed by washing with cold PBS for 3 times. 
The cells were then lysed by incubating on ice for 30 min with CelLytic M cell lysis reagent (Sigma) with 1% 
protease inhibitor cocktail. After a 30-min centrifugation at 9,000 g and at 4 °C, the resulting supernatants of cell 
lysates were collected. For SILAC labeling, the cells were cultured in SILAC medium containing unlabeled lysine 
and arginine, or [13C6, 15N2]-lysine and [13C6]-arginine for at least five cell doublings. The initial passage numbers 
for the melanoma cells were: WM-115 (p9), WM-266-4 (p6), IGR-39 (p4), IGR-37 (p7), WM-793 (p16), 1205Lu 
(p70).
plasmids and siRnAs. The sequences for siJAK3 were 5′-GGGUCCUUCACCAAGAUUU-3′ and 
5′-CCAUGGUGCAGGAAUUUGU-3′ (Dharmacon Inc)41, and RNAiMAX (Invitrogen) was employed as the 
transfection reagent following the supplier’s recommended protocol, where non-targeting siRNA (Dharmacon, 
D-001210-02-20) was the control. The MIG and the MIG-JAK3 (wild-type) plasmids were kindly provided by Dr. 
Kara Johnson at Oregon Health and Science University.
tryptic digestion of whole-cell protein lysates, and Lc-pRM analyses. A previously reported 
filter-aided sample preparation (FASP) protocol was used to generate tryptic peptides for LC-PRM analysis12,42. 
Four replicates (2 forward and 2 reverse SILAC labeling experiments) of lysates from the WM-115/WM-266-4 
pair and 2 replicates (1 forward and 1 reverse SILAC labeling experiments) each of lysates from the IGR-39/IGR-
37 and WM-793/1205Lu pairs were prepared for LC-PRM analyses. Peptide mixtures (500 ng) were subsequently 
dried in a Speed-vac, desalted with OMIX C18 pipette tips (Agilent Technologies), and analyzed by LC-MS and 
MS/MS on a Q Exactive Plus quadruple-Orbitrap mass spectrometer (Thermo Fisher Scientific) in the PRM 
mode. The mass spectrometer was coupled with an EASY-nLC 1200 system, and detailed LC-MS/MS conditions 
were described elsewhere12.
All raw files were processed using Skyline (version 3.5) for plotting the extracted-ion chromatograms and 
for peak integration43, where a previously described Skyline PRM kinome library was employed for PRM data 
acquisition and analysis12. Up to four most abundant distinct peptides for each kinase with at most one tryptic 
mis-cleavage site were included in the library. For peptide identification and quantification, we selected 6 most 
abundant y ions found in MS/MS obtained from shotgun proteomic analysis, where a ≤20 ppm mass accuracy 
was imposed in Skyline for fragment ions during peptide identification. We manually inspected all targeted pep-
tides to make sure that the chromatographic profiles for fragment ions derived from the light and heavy forms of 
the same peptide can be overlaid. We also ensured that the distributions of relative intensities of multiple transi-
tions associated with the same precursor ion are correlated with the theoretical distribution in the kinome MS/
MS spectral library entry, where we imposed a dot product (dotp) value23 of at least 0.7. The sum of peak areas 
from all transitions of light or heavy peptides was used for quantification44–46, and no other adjustments were 
made. The relative standard deviations (RSD) for kinase protein quantification were 17.2%, 16.9% and 16.4% for 
WM-115/WM-266-4, IGR-39/IGR-37 and WM-793/1205Lu pairs of cell lines, respectively (Table S1). Hence, we 
imposed a 1.5-fold cutoff when considering the expression levels of a kinase to be significantly different in the 
paired primary/metastatic melanoma cells.
tcGA, ccLe and Geo data analysis. OncoLnc was employed for the analysis of The Cancer Genome 
Atlas (TCGA) data to reveal the correlation between patient survival and kinase gene expression26, where the top 
and bottom quartiles of expression values were considered as high and low groups, respectively. The Log-rank 
p-values for each kinase are calculated individually from the survival distributions of patients with high (top 
quartile) and low (bottom quartile) expression, and were not adjusted for multiple testing. Survival differences 
with logrank p-values of <0.05 were considered significant.
Scatter plots were generated for the mRNA expression in melanoma cell lines and tissues based on the data 
retrieved from the Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle)47, and the 
GSE8401 dataset from the NCBI Gene Expression Omnibus (GEO). Box-and-whisker plot showing the mRNA 
levels of JAK3 gene in different types of cancer cells was obtained from CCLE database.
The detailed experimental conditions for Western blot, migration and invasion assay, and gel zymography 
assay are described in the Supplementary Materials.
Data availability
All the raw files for LC-PRM analyses of kinases were deposited into PeptideAtlas with the identifier number of 
PASS01179 (http://www.peptideatlas.org/PASS/PASS01179).
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